Benefits of mTOR kinase targeting in oncology: pre-clinical evidence with AZD8055
Gayle Marshall(Medicines Discovery Catapult), Sylvie M. Guichard(Novo Nordisk (United Kingdom)), Heather Keen(AstraZeneca (United Kingdom)), Paul D. Smith(Epworth Hospital), Sarah V. Holt(Pharma Nord (United Kingdom)), Jonathan R. Dry(AstraZeneca (United Kingdom)), Zoë Howard(United States Department of Defense), Neil Gray(AstraZeneca (United Kingdom)), Dan Heathcote(AstraZeneca (United Kingdom)), Armelle Logié(Sorbonne Université), Sarah E. Fenton
Cited by 38
Related Papers
Bub1 is required for kinetochore localization of BubR1, Cenp-E, Cenp-F and Mad2, and chromosome congression
|Journal of Cell Science|2004|344
Amplification of the Driving Oncogene, <i>KRAS</i> or <i>BRAF</i> , Underpins Acquired Resistance to MEK1/2 Inhibitors in Colorectal Cancer Cells
|Science Signaling|2011|209
Inhibition of mTORC1/2 Overcomes Resistance to MAPK Pathway Inhibitors Mediated by PGC1α and Oxidative Phosphorylation in Melanoma
|Cancer Research|2014|205
Salmonella Enteritidis in shell eggs: Current issues and prospects for control
|Food Research International|2011|188